GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

Google scores over Samsung with Pixel 8 Pro, says GlobalData

Following the news that Google has unveiled its Pixel 8 series of smartphones; Anisha Bhatia, Senior Technology Analyst at GlobalData, a leading data and analytics company, offers her view: “Google will offer seven years of security and OS updates on its new Pixel 8 series of smartphones. This is longer than what Android rival Samsung […]
Read more

Steatosis-associated fibrosis estimator algorithm offers hope for early detection and management of NAFLD/NASH, says GlobalData

A novel diagnostic tool, the steatosis-associated fibrosis estimator (SAFE) algorithm, may revolutionize the early detection of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD, a common liver condition, often remains undiagnosed until advanced stages. The SAFE algorithm offers promising potential to enhance patient identification, enabling proactive healthcare interventions and alleviating the burden on […]
Read more

Novo Nordisk Wegovy’s NHS access marks milestone in obesity treatment, but challenges remain, says GlobalData

Novo Nordisk‘s obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. To maintain controlled distribution, the National Institute for Health and Clinical Excellence (NICE) will implement eligibility criteria, focusing on patients with comorbidities and specific BMI ranges. Although expected to become a leading obesity […]
Read more

European challenger altnets continue to intensify competition against incumbent telcos, finds GlobalData

In a fragmented and dynamic European enterprise telecoms market, alternative service providers, known as “altnets,” continue to grow even as competition intensifies, reveals GlobalData, a leading data and analytics company. Robert Pritchard, Principal Analyst for Enterprise Technology and Services at GlobalData, says: “In turbulent times like these, where former national telcos are largely focused on […]
Read more

Intercept acquisition by Alfasigma reflects NASH failure, says GlobalData

The acquisition of Intercept Pharmaceuticals by the Italian pharmaceutical company Alfasigma became inevitable due to the failed development of Intercept’s flagship asset, obeticholic acid, as a treatment for non-alcoholic steatohepatitis (NASH). With no advanced assets left in its pipeline and rapidly declining share prices, Intercept had a compelling reason to pursue acquisition, says GlobalData, a […]
Read more

GlobalData highlights importance of World Contraception Day in promoting patient education and choice in female contraception

September 26 marks World Contraception Day across the world. An essential gap in the realm of female contraception revolves around educating patients about the diverse contraceptive options at their disposal. World Contraception Day plays a vital role in promoting awareness regarding available contraceptive methods, empowering young individuals to make well-informed decisions regarding their sexual health, […]
Read more

China pulls down APAC IPO activity in first eight months of 2023, reveals GlobalData

The Asia-Pacific (APAC) initial public offerings (IPOs) market has continued to grapple with disruptions, including the lingering impact of COVID-19, the Russia-Ukraine conflict, rising inflation, and geopolitical tensions. In the first eight months of 2023, APAC saw a significant decline in IPO activity, with 491 listings totaling $44.4 billion, down by 55.9% compared to the […]
Read more

New generics in idiopathic pulmonary fibrosis space will provide more access to patients, says GlobalData

The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments which are available globally, Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s (BI) Ofev (nintedanib), which were both approved by the FDA in 2014. Since the patent expiration of Esbriet in 2021, new generic versions have begun entering the IPF space providing more […]
Read more
1 … 89 90 91 92 93 … 209